HilleVax is focused on developing a vaccine to combat norovirus, a leading cause of acute gastroenteritis globally. Their primary candidate, HIL-214, is a bivalent virus-like particle (VLP) vaccine designed to provide active immunization against norovirus strains GI.1 and GII.4. This innovative approach utilizes VLP technology, which mimics the structure of the virus without containing its genetic material, thereby stimulating an immune response without causing disease. HIL-214 has undergone extensive clinical testing, including nine Phase 1 and Phase 2 trials involving over 4,500 participants, demonstrating its safety and efficacy in preventing moderate-to-severe cases of norovirus-related gastroenteritis.

The significance of HilleVax's work is underscored by the substantial global burden of norovirus, which is responsible for millions of illnesses and significant economic costs each year. The vaccine aims to address the challenges posed by norovirus, including its resilience on surfaces and resistance to common disinfectants. By targeting vulnerable populations, such as young children and older adults, HilleVax's HIL-214 has the potential to significantly reduce the incidence of norovirus infections and their associated health impacts, ultimately contributing to public health improvements and economic savings.

United States

HilleVax, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel vaccines. It is developing HIL-214, a virus-like particle-based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection. The company is headquartered in Boston, Massachusetts.

HilleVax

Company Details